September 5, 2008
ProFACT Proteomics, Inc. Appoints Two Territorial Sales Agents

North Brunswick, NJ, September 5, 2008: ProFACT Proteomics, Inc. has appointed two new sales agents to canvas exclusive territories promoting its functional proteomic services: Robert Jones, Ph.D. for Pennsylvania (Tel: 570-449-0103), and Millennium Technologies and Services for the midwestern US states along with Ontario and Quebec provinces in Canada (Tel: 216-374-8687).

About ProFACT Proteomics, Inc.

ProFACT Proteomics, Inc. is a privately held early-stage corporation which applies its enabling proprietary Proteomics technology, for development of therapeutics, diagnostics and personalized medicine, principally for cancer. Through partnership and service agreements, ProFACT participates in 4 key platform areas: SeraFILE™, for reduction of protein complexity and sub-proteome creation; Rational Proteome Prospecting™, to enrich and isolate functional activity; Conformerics™, to generate drug screening assays based on enzyme sub-states or conformers; and Rational Genome to Proteome Prospecting™, for prospecting into protein expression based on gene expression data.



July 23, 2008
ProFACT Proteomics, Inc. Awarded New Jersey Incubator Seed Fund Grant

North Brunswick, NJ, July 23, 2008: ProFACT Proteomics, Inc. is to be awarded an Incubator Seed Fund Grant as announced by the New Jersey Commission on Science and Technology on June 24, 2008. The funds will support development and filing of up to six new patents enhancing its platform tools in drug target and biomarker discovery.

About ProFACT Proteomics, Inc.

ProFACT Proteomics, Inc. is a privately held early-stage corporation which applies its enabling proprietary Proteomics technology, for development of therapeutics, diagnostics and personalized medicine, principally for cancer. Through partnership and service agreements, ProFACT participates in 4 key platform areas: SeraFILE™, for reduction of protein complexity and sub-proteome creation; Rational Proteome Prospecting™, to enrich and isolate functional activity; Conformerics™, to generate drug screening assays based on enzyme sub-states or conformers; and Rational Genome to Proteome Prospecting™, for prospecting into protein expression based on gene expression data.



March 24, 2008
Profact Proteomics Poster at HUPO Conference



February 8, 2008
ProFACT appoints Kensington Bio as its exclusive sales agent for Maryland, DC, Virginia, Delaware and North Carolina.



December 25, 2007
ProFACT introduces its proprietary platform SeraFILE, for the reduction of protein complexity, and sub-proteome creation.